This inventor holds 1 USPTO granted patent and 3 published patent applications and 1 EPO patent. Top assignee: Eisai R&d Management Co., Ltd.. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: Alton Kremer: Pioneering Combination Therapies for Cancer Treatment
Introduction
Alton Kremer, an accomplished inventor based in Weston, Connecticut, has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on the potential of combining eribulin with poly (ADP ribose) polymerase (PARP) inhibitors to enhance therapeutic outcomes in cancer patients.
Latest Patents
Kremer holds a noteworthy patent titled "Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer." This patent outlines methods for treating patients suffering from cancer by administering eribulin alongside one or more PARP inhibitors, with the optional inclusion of platinum-based antineoplastic drugs. The invention is particularly significant as it is based on the observation that these combinations lead to improved antitumor effects, specifically in cancers deficient in homologous recombination.
Career Highlights
Alton Kremer works at Eisai R&D Management Co., Ltd., where he has dedicated his efforts to advancing cancer treatments through innovative therapeutic strategies. His patent signifies a major advancement in combining existing therapies to create more effective treatment options for patients facing challenging cancer diagnoses.
Collaborations
Throughout his career, Kremer has collaborated with notable peers, including David Cox and Sharon McGonigle. These collaborations emphasize the importance of teamwork in the innovation process, allowing for the pooling of expertise and resources to achieve groundbreaking results in cancer therapy.
Conclusion
Alton Kremer's inventive approach to cancer treatment through the combination of eribulin and PARP inhibitors exemplifies the potential of innovation in medicine. His contributions not only highlight the significance of patenting novel methodologies but also underscore the collaborative efforts required to push the boundaries of current medical therapies, ultimately aiming to improve patient outcomes in the fight against cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile